13 April 2018, Paris, France: The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy (SIRT) to standard sorafenib treatment compared with using sorafenib alone. However, although the overall survival rates in the total patient population did not differ significantly between treatment groups, subgroup analyses suggested possible survival benefits with adding SIRT to sorafenib in some patient groups.
‘SORAMIC is the first large, randomized controlled trial to compare the efficacy and safety of combining liver-directed SIRT and sorafenib with using sorafenib alone’, explained study director, Prof. Dr Jens Ricke from the Ludwig-Maximilians-University in Munich, Germany, who presented the results today at The International Liver Congress™ 2018 in Paris, France. ‘Although we were disappointed to find no overall survival benefit of adding SIRT to sorafenib across the entire study population, we did observe a survival benefit in younger patients, those with a non-alcoholic aetiology of the cirrhosis, and those with no cirrhosis at all’.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the second most common cause of cancer-related death.1,2 HCC can be treated
Article originally posted at